Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET

Journal of Nuclear Medicine

Volumn 53, Issue 3, 2012, Pages 359-362

  Van Nostrand, Douglas ^a   Khorjekar, Gauri R ^a   O'Neil, Jeff ^a   Moreau, Shari ^a   Atkins, Frank B ^a   Kharazi, Pejman ^a   Mete, Mihriye ^a   Chennupati, Shyam P ^a   Burman, Kenneth D ^a   Wartofsky, Leonard ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

124I; 131I; Recombinant human thyroid stimulating hormone; Thyroid cancer; Thyroid hormone withdrawal

Indexed keywords

IODINE 124; IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE;

ADULT; ARTICLE; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOSIMETRY; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; METASTASIS; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; WHOLE BODY IMAGING;

ADULT; AGED; BIOPSY, FINE-NEEDLE; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; THYROGLOBULIN; THYROID FUNCTION TESTS; THYROID HORMONES; THYROID NEOPLASMS; THYROTROPIN; WHOLE BODY IMAGING;

EID: 84858603187     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.096016     Document Type: Article

References (12)

1. Pacini F, Molinaro E, Castagna MG, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinomas: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926-932. (Pubitemid 43357760)
2. Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 2005;12:49-64. (Pubitemid 40477087)
3. 131I treatment of metastatic differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:2264-2266.
4. 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging. 2010;37:2267-2276.
5. Pötzi C, Moameni A, Karanikas G, et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf). 2006;65:519-523. (Pubitemid 44414277)
6. Driedger AA, Kotowycz N. Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin. J Clin Endocrinol Metab. 2004;89: 585-590. (Pubitemid 38269862)
7. Taïeb D, Jacob T, Zotina E, Mundler O. Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. Thyroid. 2004;14:465-467. (Pubitemid 38868768)
8. Hung GU, Minglin H, Kao CH. Faster radioiodine washout in the treatment of pulmonary metastases of papillary thyroid cancer prepared with recombinant human thyroid-stimulating hormone. Clin Nucl Med. 2009;34:316-317.
9. 131I ablation in patients with well-differentiated thyroid cancer. Thyroid. 2009;19:849-855.
10. 131I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid. 2010;20:879-883.
11. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, et al. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid. In press.
12. Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab. 2011;96:2105-2111.